Name: Sunitinib Malate Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH3404
Price: 4350 USD
Availability: InStock

Sunitinib Malate Market Size Share Growth Opportunities and Forecast 2022

Sunitinib Malate Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Sunitinib Malate Market&nbsp;is segmented&nbsp;By Type (Purity: Above 99%, Purity: Above 98%, Purity: Above 97%), By Application (Pancreatic Neuroendocrine Tumors, Kidney Cancer, Gastrointestinal stromal tumor, Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The Global Sunitinib Malate Market is expected to grow at a&nbsp;CAGR&nbsp;during the forecasting period (2022-2029).
</blockquote>

Sunitinib Malate is a specific small molecule, orally bioavailable malate salt of the indolinone-based multi-focused receptor tyrosine kinase (RTK) inhibitor asserted by the U.S. Food and Drug Administration for cancer treatment. Sunitinib cases have been approved for treating pancreatic neuroendocrine tumors, gastrointestinal stromal tumour (GIST), and kidney cancer.

The drug comprises an oral multikinase inhibitor that blocks multiple molecular growth receptors and prevents the spread of cancer. The drug stops the extension of vascular endothelial growth factor receptors (VEGFR), platelet-derived extension factor receptors (PDGFR) and KIT.

Sunitinib malate capsules have received the U.S. Food and Drug Administration approval for treating GIST renal cell carcinoma and renal cell carcinoma in January 2006. They also consequently received approval from the European Medicine Agency in July 2006. Two years next, on April 16, 2008, the drug was approved by Japan&rsquo;s Pharmaceuticals and Medical Devices Agency (PMDA).

<h2>Market Dynamics</h2>

The sunitinib malate market growth is driven by the increasing prevalence of pancreatic cancer coupled with increasing awareness about pancreatic cancer in emerging countries is expected to drive the market&#39;s growth.

The increasing prevalence of pancreatic cancer will drive the market growth

The growing prevalence of pancreatic cancer is a significant driver for the market. As per the American Cancer Society, around 53,000 Americans are diagnosed with pancreatic cancer in 2016, among close to 42,000 of them accede to it. Due to the related inaccessibility of the pancreas, identifying and removing pancreatic growths is more complex than other tumors. As a consequence, the use of sunitinib malate to treat pancreatic tumors is increasing.

The FDA approved sunitinib malate in May 2011 for the treatment of pancreatic neuroendocrine tumors that have proven challenging to extract surgically or have already metastasized.

Furthermore, the convenience of an inadequate quantity of drug therapeutics for the therapy of advanced pancreatic neuroendocrine tumors and poor diagnosis rate in the beginning phases of pancreatic cancer increases the requirement for sunitinib malate in the treatment of pancreatic cancer. Increasing healthcare expenditure and growing population will expand the market. The drugs under the pipeline and the rising scope for cancer therapy are drivers in the global sunitinib malate market.

The availability of a limited number of drug therapeutic options for the treatment is driving the market growth

Since its primary characterization, pancreatic cancer has remained one of the most deadly and difficult cancers to operate. Pancreatic cancer is the fourth foremost cause of death in the United States, rising in an estimated 38460 deaths annually. Besides few screening tools available to identify this disease at an early stage, 94% of patients will die within five years of treatment, despite decades of research that have led to a more solid understanding of the cellular and molecular signalling pathways in pancreatic cancer cells.&nbsp; Other treatment alternatives have included more sophisticated pancreatic cancer surgeries and combination therapies. While results have recovered modestly for these patients, more efficient treatments are desperately needed. Thus there are very few medications available in the market for their treatment. These factors will drive the market growth in the forecast period.

Side effects coupled with the high cost will hamper the market growth

However, one of the factors acting against the market&#39;s growth is the high cost of Sutent. It stands among the most costly drugs currently being marketed, which puts it out of the average consumer&#39;s reach in the lack of sufficient reimbursement. For 28 capsules of Sutent, 37.5mg average cash price is $17,968.99. Some side effects of Sutent, such as Hepatotoxicity and Adverse cardiovascular events like heart failure, myocardial infarction and coronary artery bypass grafting, have also been reported during clinical trials, which could discourage drug adoption.

COVID-19 Impact Analysis

According to the CDC, the senior population with underlying severe therapeutic conditions, including people with cancer, might be at higher risk for severe illness from COVID-19. Patients with pancreatic cancer are at higher risk for severe COVID-19 than those without pancreatic cancer.

According to a research article by Hidenori Toyoda et al., published in Hepatology Communications Journal 2020, during the COVID‐19 pandemic 2020, strict measures were implemented by the government to prevent the spread of COVID-19, which adversely affected the routine monitoring of cancers. Therefore, these patients were considered in the emergency category during the pandemic. Besides, the increased sales of this drug will foster healthy growth of the market amid COVID-19.

<h2>Segment Analysis</h2>

By application, the Sunitinib malate market is classified into pancreatic neuroendocrine tumors, kidney cancer, gastrointestinal stromal tumor, others.

The pancreatic neuroendocrine tumors segment is expected to grow at the fastest CAGR during the forecast period (2021-2028) &nbsp;&nbsp;

Pancreatic neuroendocrine tumors (NET), also known as islet cell tumors, are rare tumors of the endocrine pancreas. They form due to the hormone-producing cells in the pancreas. About 90% of the non-functional neuroendocrine tumors are cancerous. It was found that about 90% of the patients with pancreatic NET were initially diagnosed with locally advanced or metastatic cancer. Patients with pancreatic NET in an advanced or metastatic stage can survive for one to three years. The disease is rare cancer reported in two to four people per million each year worldwide.

Some pancreatic neuroendocrine tumor cells extend to secrete hormones (known as functional tumors), producing too much of the given hormone in your body. Examples of these types include glucagonoma and gastrinoma. These tumors often do not secrete an excess amount of these hormones (known as nonfunctional tumors).

Functional neuroendocrine tumors create the pancreas to overproduce hormones, consequently making hormone-related symptoms. The majority of NETs are nonfunctional tumors. Nonfunctional tumors do not produce any hormones, so people do not cause any hormone-related indications. As a result, these tumors are typically diagnosed once the tumor is advanced and generates symptoms such as pain or jaundice.

Based on therapy, the Sunitinib Malate Market is classified into targeted therapy radiation therapy, immunotherapy, chemotherapy.

<h2>Geographical Analysis</h2>

North America region holds the largest market share in the global Sunitinib Malate Market 

North America region is dominating the global sunitinib malate market accounted for the largest market share in 2020, owing to the growing incidence of pancreatic cancer in the region, the presence of key market players, and the launch of new commodities influence market growth in the region. For instance, the region has emerged as the leading market for sunitinib malate capsules, which are marketed by Pfizer as Sutent.

Pfizer has market exclusivity over sunitinib malate capsules until 2021, which has made them an important revenue source for Pfizer, which had been losing revenue due to Lipitor&#39;s patent expiration in November 2011, estimated at more than US$1 Bn as of 2015.

On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period due to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and effective treatment in emerging countries, such as China and India.

<h2>Competitive Landscape</h2>

The sunitinib malate market is moderately competitive with the presence of local as well as global companies. &nbsp;Some of the key players which are contributing to the growth of the market include Pfizer, Topcare pharmaceutical Co. Ltd, Nanjing First Pharmaceutical Co. Ltd., J&amp;K Scientific, Target Molecule Corp., Medichem, Biotechnica Pharma Global, Beijing Lunarsun Pharmaceutical Co. LTD, Brawn Laboratories Ltd INDIA, Hetero Drugs Ltd, Hikma Pharmaceutical plc among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the sunitinib malate market globally. &nbsp;&nbsp;&nbsp;

Pfizer Inc.&nbsp; 

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients&#39; lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&amp;D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company&rsquo;s portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Why Purchase the Report?

<ul>
	<li>Visualize the composition of the sunitinib malate market segmentation by type, application, and end-user highlighting the key commercial assets and players.</li>
	<li>Identify commercial opportunities in the sunitinib malate market by analyzing trends and co-development deals.</li>
	<li>Excel data sheet with thousands of data points of sunitinib malate market-level 4/5 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global sunitinib malate market report would provide an access to an approx. 61 market data table, 54 figures and 180 pages. &nbsp;

Target Audience

<ul>
	<li>Service Providers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Education &amp; Research Institutes</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
	<li>Manufacturers</li>
</ul>

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/immunology-drugs-market">Immunology Drugs Market</a>

<a href="https://www.datamintelligence.com/research-report/oncology-nutrition-market">Oncology Nutrition Market</a>

<a href="https://www.datamintelligence.com/research-report/cancer-stem-cells-market">Cancer Stem Cells Market</a>

<a href="https://www.datamintelligence.com/research-report/oncology-therapy-market">Oncology Therapy Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>Market Snippet by Type</li>
		<li>Market Snippet by Application</li>
		<li>Market Snippet by End User</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing prevalence of pancreatic cancer will drive the market growth</li>
				<li>The availability of a limited number of drug therapeutic options for the treatment is driving the market growth</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Side effects coupled with high cost of will hamper the market growth</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>
	<h3>COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment</li>
			<li>Market Attractiveness Index, By Type &nbsp;Segment</li>
		</ol>
		</li>
		<li>Purity: Above 99%*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Purity: Above 98%</li>
		<li>Purity: Above 97%</li>
	</ol>
	</li>
	<li>
	<h3>By Application</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Attractiveness Index, By Application</li>
		</ol>
		</li>
		<li>Pancreatic Neuroendocrine Tumors*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Kidney Cancer</li>
		<li>Gastrointestinal stromal tumor</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By End User</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment</li>
			<li>Market Attractiveness Index, By End User Segment</li>
		</ol>
		</li>
		<li>Hospitals *
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Clinics</li>
		<li>&nbsp;Ambulatory Surgical Centers &nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Competitive Landscape</h3>

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
	</ol>
	</li>
	<li>
	<h3>Company Profiles</h3>

	<ol>
		<li>Pfizer. *
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>UCB SA</li>
		<li>Topcare pharmaceutical Co. Ltd</li>
		<li>Nanjing First Pharmaceutical Co. Ltd.</li>
		<li>J&amp;K Scientific</li>
		<li>Target Molecule Corp.</li>
		<li>Medichem</li>
		<li>Biotechnica Pharma Global</li>
		<li>Beijing Lunarsun Pharmaceutical Co. LTD</li>
		<li>Brawn Laboratories Ltd(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence&nbsp;&nbsp;</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 01&nbsp;&nbsp; Global Sunitinib Malate Market Value, By Type, 2021, 2025 &amp; 2029($ Million)

Table 02&nbsp;&nbsp; Global Sunitinib Malate Market Value, By Application, 2021, 2025 &amp; 2029($ Million)

Table 03&nbsp;&nbsp; Global Sunitinib Malate Market Value, By End User, 2021, 2025 &amp; 2029($ Million)

Table 04&nbsp;&nbsp; Global Sunitinib Malate Market Value, By Region, 2021, 2025 &amp; 2029($ Million)

Table 05&nbsp;&nbsp; Global Sunitinib Malate Market Value, By Type, 2021, 2025 &amp; 2029($ Million)

Table 06&nbsp;&nbsp; Global Sunitinib Malate Market Value, By Type, 2018-2029($ Million)

Table 07&nbsp;&nbsp; Global Sunitinib Malate Market Value, By Application, 2021, 2025 &amp; 2029($ Million)

Table 08&nbsp; Global Sunitinib Malate Market Value, By Application, 2018-2029($ Million)

Table 09&nbsp;&nbsp; Global Sunitinib Malate Market Value, By End User, 2021, 2025 &amp; 2029($ Million)

Table 10&nbsp;&nbsp; Global Sunitinib Malate Market Value, By End User, 2018-2029($ Million)

Table 11&nbsp;&nbsp;&nbsp; Global Sunitinib Malate Market Value, By Region, 2021, 2025 &amp; 2029($ Million)

Table 12&nbsp;&nbsp; Global Sunitinib Malate Market Value, By Region, 2018-2029($ Million)

Table 13&nbsp;&nbsp; North America Sunitinib Malate Market Value, By Type, 2018-2029($ Million)

Table 14&nbsp;&nbsp; North America Sunitinib Malate Market Value, By Application, 2018-2029($ Million)

Table 15&nbsp;&nbsp; North America Sunitinib Malate Market Value, By End User, 2018-2029($ Million)

Table 16&nbsp;&nbsp; North America Sunitinib Malate Market Value, By Country, 2018-2029($ Million)

Table 17&nbsp;&nbsp;&nbsp; South America Sunitinib Malate Market Value, By Type, 2018-2029($ Million)

Table 18&nbsp;&nbsp; South America Sunitinib Malate Market Value, By Application, 2018-2029($ Million)

Table 19&nbsp;&nbsp; South America Sunitinib Malate Market Value, By End User, 2018-2029($ Million)

Table 20&nbsp;&nbsp; South America Sunitinib Malate Market Value, By Country, 2018-2029($ Million)

Table 21&nbsp;&nbsp; Europe Sunitinib Malate Market Value, By Type, 2018-2029($ Million)

Table 22&nbsp;&nbsp; Europe Sunitinib Malate Market Value, By Application, 2018-2029($ Million)

Table 23&nbsp;&nbsp; Europe Sunitinib Malate Market Value, By End User, 2018-2029($ Million)

Table 24&nbsp;&nbsp; Europe Sunitinib Malate Market Value, By Country, 2018-2029($ Million)

Table 25&nbsp;&nbsp; Asia-Pacific Sunitinib Malate Market Value, By Type, 2018-2029($ Million)

Table 26&nbsp;&nbsp; Asia-Pacific Sunitinib Malate Market Value, By Application, 2018-2029($ Million)

Table 27&nbsp;&nbsp; Asia-Pacific Sunitinib Malate Market Value, By End User, 2018-2029($ Million)

Table 28&nbsp;&nbsp; Asia-Pacific Sunitinib Malate Market Value, By Country, 2018-2029($ Million)

Table 29&nbsp;&nbsp; Middle East &amp; Africa Sunitinib Malate Market Value, By Type, 2018-2029($ Million)

Table 30&nbsp;&nbsp; Middle East &amp; Africa Sunitinib Malate Market Value, By Application, 2018-2029($ Million)

Table 31&nbsp;&nbsp; Middle East &amp; Africa Sunitinib Malate Market Value, By End User, 2018-2029($ Million)

Table 32&nbsp;&nbsp; Pfizer: Overview

Table 33&nbsp;&nbsp; Pfizer: Product Portfolio

Table 34&nbsp;&nbsp; Pfizer: Key Developments

Table 35&nbsp;&nbsp; Topcare pharmaceutical Co. Ltd: Overview

Table 36&nbsp;&nbsp; Topcare pharmaceutical Co. Ltd: Product Portfolio

Table 37&nbsp;&nbsp; Topcare pharmaceutical Co. Ltd: Key Developments

Table 38&nbsp;&nbsp; Nanjing First Pharmaceutical Co. Ltd.: Overview

Table 39&nbsp;&nbsp; Nanjing First Pharmaceutical Co. Ltd.: Product Portfolio

Table 40&nbsp;&nbsp; Nanjing First Pharmaceutical Co. Ltd.: Key Developments

Table 41&nbsp;&nbsp; J&amp;K Scientific: Overview

Table 42&nbsp;&nbsp; J&amp;K Scientific: Product Portfolio

Table 43&nbsp;&nbsp; J&amp;K Scientific: Key Developments

Table 44&nbsp;&nbsp; Target Molecule Corp.: Overview

Table 45&nbsp;&nbsp; Target Molecule Corp.: Product Portfolio

Table 46&nbsp;&nbsp; Target Molecule Corp.: Key Developments

Table 47&nbsp;&nbsp; Medichem: Overview

Table 48&nbsp;&nbsp; Medichem: Product Portfolio

Table 49&nbsp;&nbsp; Medichem: Key Developments

Table 50&nbsp;&nbsp; Biotechnica Pharma Global: Overview

Table 51&nbsp;&nbsp; Biotechnica Pharma Global: Product Portfolio

Table 52&nbsp;&nbsp; Biotechnica Pharma Global: Key Developments

Table 53&nbsp;&nbsp; Beijing Lunarsun Pharmaceutical Co. LTD: Overview

Table 54&nbsp;&nbsp; Beijing Lunarsun Pharmaceutical Co. LTD: Product Portfolio

Table 55&nbsp;&nbsp; Beijing Lunarsun Pharmaceutical Co. LTD: Key Developments

Table 56&nbsp;&nbsp; Brawn Laboratories Ltd INDIA: Overview

Table 57&nbsp;&nbsp; Brawn Laboratories Ltd INDIA: Product Portfolio

Table 58&nbsp;&nbsp; Brawn Laboratories Ltd INDIA: Key Developments

Table 59&nbsp;&nbsp; Jeil Pharmaceutical Co. Ltd: Overview

Table 60&nbsp;&nbsp; Jeil Pharmaceutical Co. Ltd: Product Portfolio

Table 61&nbsp;&nbsp; Jeil Pharmaceutical Co. Ltd: Key Developments&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

List of Figures

Figure 01 Global Sunitinib Malate Market Share, By Type, 2021 &amp; 2029 (%)

Figure 02 Global Sunitinib Malate Market Share, By Application, 2021 &amp; 2029 (%)

Figure 03 Global Sunitinib Malate Market Share, By End User, 2021 &amp; 2029 (%)

Figure 04 Global Sunitinib Malate Market Share, By Region, 2021 &amp; 2029 (%)

Figure 05 Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 06 Global Sunitinib Malate Market Y-o-Y Growth, By Type, 2021-2029 (%)

Figure 07 Purity: Above 99%: Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 08 Purity: Above 98%: Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 09 Purity: Above 97%: Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 10 Global Sunitinib Malate Market Y-o-Y Growth, By Application, 2021-2029 (%)

Figure 11&nbsp; Pancreatic Neuroendocrine Tumors: Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 12 Kidney Cancer: Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 13 Gastrointestinal stromal tumor: Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 14 Others: Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 15 Global Sunitinib Malate Market Y-o-Y Growth, By End User, 2021-2029 (%)

Figure 16 Hospitals &amp; Diagnostic Imaging Centers: Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 17&nbsp; Government Institutions: Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 18 Research Facilities: Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 19 Global Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 20 Global Sunitinib Malate Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 21 North America Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 22 North America Sunitinib Malate Market Share, By Type, 2021 &amp; 2029 (%)

Figure 23 North America Sunitinib Malate Market Share, By Application, 2021 &amp; 2029 (%)

Figure 24 North America Sunitinib Malate Market Share, By End User, 2021 &amp; 2029 (%)

Figure 25 North America Sunitinib Malate Market Share, By Country, 2021 &amp; 2029 (%)

Figure 26 South America Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 27 South America Sunitinib Malate Market Share, By Type, 2021 &amp; 2029 (%)

Figure 28 South America Sunitinib Malate Market Share, By Application, 2021 &amp; 2029 (%)

Figure 29 South America Sunitinib Malate Market Share, By End User, 2021 &amp; 2029 (%)

Figure 30 South America Sunitinib Malate Market Share, By Country, 2021 &amp; 2029 (%)

Figure 31 Europe Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 32 Europe Sunitinib Malate Market Share, By Type, 2021 &amp; 2029 (%)

Figure 33 Europe Sunitinib Malate Market Share, By Application, 2021 &amp; 2029 (%)

Figure 34 Europe Sunitinib Malate Market Share, By End User, 2021 &amp; 2029 (%)

Figure 35 Europe Sunitinib Malate Market Share, By Country, 2021 &amp; 2029 (%)

Figure 36 Asia-Pacific Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 37 Asia-Pacific Sunitinib Malate Market Share, By Type, 2021 &amp; 2029 (%)

Figure 38 Asia-Pacific Sunitinib Malate Market Share, By Application, 2021 &amp; 2029 (%)

Figure 39 Asia-Pacific Sunitinib Malate Market Share, By End User, 2021 &amp; 2029 (%)

Figure 40 Asia-Pacific Sunitinib Malate Market Share, By Country, 2021 &amp; 2029 (%)

Figure 41 Middle East &amp; Africa Sunitinib Malate Market Value, 2018-2029($ Million)

Figure 42 Middle East &amp; Africa Sunitinib Malate Market Share, By Type, 2021 &amp; 2029 (%)

Figure 43 Middle East &amp; Africa Sunitinib Malate Market Share, By Application, 2021 &amp; 2029 (%)

Figure 44 Middle East &amp; Africa Sunitinib Malate Market Share, By End User, 2021 &amp; 2029 (%)

Figure 45 Pfizer: Financials

Figure 46 Topcare pharmaceutical Co. Ltd: Financials

Figure 47 Nanjing First Pharmaceutical Co. Ltd.: Financials

Figure 48 J&amp;K Scientific: Financials

Figure 49 Target Molecule Corp.: Financials

Figure 50 Medichem: Financials

Figure 51 Biotechnica Pharma Global: Financials

Figure 52 Beijing Lunarsun Pharmaceutical Co. LTD: Financials

Figure 53 Brawn Laboratories Ltd INDIA: Financials

Figure 54 Jeil Pharmaceutical Co. Ltd: Financials